2025 Program

Please be aware that the conference schedule is subject to change without prior notice. We recommend checking this page and our official channels for updates.

Download Schedule

Schedule

Day 1 - Friday, March 28, 2025

Time	Title	Speaker
8:00 AM	BREAKFAST AND REGISTRATION
9:00 AM	Introduction from conference organizers
9:05 AM	Opening remarks	Michael Teitell, MD, PhD University of California, Los Angeles
	PSMA Imaging Session 1
9:10 AM	History of PSMA	Martin Pomper, MD, PhD University of Texas, Southwestern
9:18 AM	Landscape of approved PSMA imaging agents: does it matter?	Amir Iravani, MD University of Washington
9:26 AM	Pictorial Atlas of PSMA PET	Matthias Benz, MD University of California, Los Angeles
9:34 AM	Impact of clinical guidelines on the utilization of PSMA PET	Emmanuel Antonarakis, MD University of Minnesota
9:42 AM	Panel discussion
	PSMA Imaging Session 2
9:50 AM	Who benefits from oligo-metastases directed therapy?	Julian Hong, MD, MS University of California, San Francisco
9:58 AM	PSMA-PET for overall survival outcomes risk stratification of prostate cancer	Wolfgang Fendler, MD University Hospital Essen, Germany
10:06 AM	WB PSMA quantitative parameters: Why are we not using WB PSMA PET parameters in the real world?	Irene Buvat, PhD Institut Curie, Orsay, France
10:14 AM	Panel discussion
10:20 AM	COFFEE BREAK
	PSMA Imaging Session 3
10:35 AM	The changing role of MRI in staging patients with prostate cancer	Steven Raman, MD University of California, Los Angeles
10:43 AM	Role of PSMA PET in surgical planning and post-operative management	Carissa Chu, MD University of California, San Francisco
10:51 AM	PSMA PET fusion guided biopsy	Wayne Brisbane, MD University of California, Los Angeles
10:59 AM	PRIMARY score and where it plays a role	Michael Hofman, FRACP, MBBS Peter MacCallum Cancer Centre, Melbourne, Australia
11:07 AM	Panel discussion
	PSMA Imaging Session 4
11:15 AM	Can we kill the bone scan?	Daniel Spratt, MD University Hospitals, Cleveland, OH
11:23 AM	How to crush a PSMA PET report: guidelines and scoring systems	Phillip Kuo, MD, PhD City of Hope, Los Angeles
11:31 AM	Incorporating PSMA PET into trial endpoints	Michael Morris, MD Memorial Sloan Kettering, New York
11:39 AM	Panel discussion + mini tumor board 1 [PET imaging]	Wayne Brisbane, MD Amir Iravani, MD Phillip Kuo, MD, PhD Michael Morris, MD Daniel Spratt, MD
12:15 PM	LUNCH BREAK
	LuPSMA Therapy Session 1
1:15 PM	Path to Clinical Use: Lesson from compassionate use in Germany	Wolfgang Fendler, MD University Hospital Essen, Germany
1:23 PM	Post-VISION: Real world experience in the US, how is PSMA RLT being used?	Matthew Rettig, MD University of California, Los Angeles
1:31 PM	Radiation Safety and Ecology: Comparison of practices across the US and the world	Catherine Meyer, PhD University of California, Los Angeles
1:39 PM	Panel discussion
	LuPSMA Therapy Session 2
1:45 PM	Pre-chemo trials: PSMAfore/SPLASH/ECLIPSE	Emmanuel Antonarakis, MD University of Minnesota
1:53 PM	Moving into the castration sensitive setting	Michael Morris, MD Memorial Sloan Kettering Cancer Center
2:01 PM	PSMA RLT for oligometastatic disease	Amar Kishan, MD University of California, Los Angeles
2:09 PM	Overview of enrolling Phase 2/3 trials	Jeremie Calais, MD, PhD University of California, Los Angeles
2:17 PM	Panel discussion
2:25 PM	COFFEE BREAK
	LuPSMA Therapy Session 3
2:40 PM	When should we use FDG PET?	Andrei Iagaru, MD Stanford University, California
2:48 PM	What’s the best way to evaluate response: SPECT vs PSMA PET?	Thomas Hope, MD University of California, San Francisco
2:56 PM	Moving beyond 6x6	Matthias Eiber, MD, PhD Technische Universität München, Germany
3:04 PM	Treatment Sequencing	Tanya Barauskas Dorff, MD City of Hope, Los Angeles
3:12 PM	*Panel discussion + mini tumor board 2 [PSMA RLT]*	Emmanuel Antonarakis, MD Tanya Barauskas Dorff, MD Matthias Eiber, MD, PhD Andrei Iagaru, MD Amar Kishan, MD
3:45 PM	Wrap up for the day
3:50 PM	Poster power pitches
4:05 PM	Poster session reception
4:50 PM	Poster awards + Closing

Day 2 - Saturday, March 29, 2025

Time	Title	Speaker
8:00 AM	BREAKFAST
	Dosimetry Session
9:00 AM	Are we underdosing?	Amir Iravani, MD University of Washington
9:08 AM	Lessons from radiation oncology: How can we improve PSMA RLT?	Daniel Spratt, MD University Hospitals, Cleveland, OH
9:16 AM	“Beyond the 23 Gray threshold”	Ana Ponce Kiess, MD, PhD Johns Hopkins University, Baltimore, MD
9:24 AM	How to use quantitative dosimetry and act on it to adapt treatment	Carlos Uribe, PhD,MCCPM BC Cancer, University of British Columbia
9:32 AM	AI for Dosimetry	Irene Buvat, PhD Institut Curie, Orsay, France
9:40 AM	Panel discussion
	LuPSMA Therapy Session 4
9:50 AM	How are we getting paid for Theranostics and Dosimetry?	Denise Merlino, CPC, MBA, CNMT Merlino Healthcare Consulting, Florida
9:58 AM	PSMA RLT in a Medical Oncology private center	Luke Nordquist, MD Xcancer, Omaha, NE
10:06 AM	PSMA RLT in a Radiation Oncology private center	Dustin Boothe, MD Intermountain Health, Salt Lake City, UT
10:14 AM	Patient Experience	Mr. Kent Greer UCLA patient
10:22 AM	Panel discussion
10:30 AM	COFFEE BREAK
	Antibody and Other Ligands Session
10:45 AM	PSMA-I&T vs PSMA-617: Is there a difference?	Matthias Eiber, MD, PhD Technische Universität München, Germany
10:53 AM	Role of PSMA targeted antibodies	Scott Tagawa, MD, MS Weill Cornell Medicine, New York
11:01 AM	Next generation PSMA radioligands	Martin Pomper, MD, PhD University of Texas, Southwestern
11:09 AM	Panel discussion
	Alpha and Other Radionuclides Session
11:20 AM	How PSMA RLT kills the cells? Alpha vs beta radiobiology	Ana Ponce Kiess, MD, PhD Johns Hopkins University, Baltimore, MD
11:28 AM	Ac225 PSMA experience	Alfred Morgenstern, PhD Joint Research Centre, Karlsruhe, Germany
11:36 AM	Management of dry mouth	Sue Yom, MD, PhD University of California, San Francisco
11:44 AM	Pb212 PSMA vs Ac225 PSMA: From biology to supply	Alfred Morgenstern, PhD Joint Research Centre, Karlsruhe, Germany
11:52 AM	Tb161 Experience at Peter MacCallum Cancer Center	Michael Hofman, FRACP,MBBS Peter MacCallum Cancer Centre, Australia
12:00 PM	Panel discussion
12:10 PM	LUNCH BREAK
	Targeting PSMA with CAR-T, ADC, BisAb: Comparison with RLT
1:10 PM	CAR-T and Bispecific Antibodies targeting PSMA	Tanya Barauskas Dorff, MD City of Hope, Los Angeles
1:18 PM	Role of ADCs in prostate cancer	John K. Lee, MD, PhD University of California, Los Angeles
1:26 PM	Value of animal models in evaluating PSMA-targeted RPT and non-RPT therapies	Deborah Charych, PhD Utter Therapeutics
1:34 PM	Panel discussion	Tanya Barauskas Dorff, MD John K. Lee, MD, PhD Matthew Rettig, MD Deborah Charych, PhD Scott Tagawa, MD, MS
	Keynote Lecture
1:50 PM	Improving outcomes with combination therapy	Michael Hofman, FRACP,MBBS Peter MacCallum Cancer Centre, Australia
2:10 PM	Panel discussion	Emmanuel Antonarakis, MD Tanya Barauskas Dorff, MD Michael Hofman, FRACP,MBBS Michael Morris, MD
	New Developments in GU Radioligand Therapy
2:25 PM	GRPR and other peptides for targeting prostate cancer	Andrei Iagaru, MD Stanford University, California
2:33 PM	DLL3, CD46, STEAP1 and others	Robert Flavell, MD, PhD University of California, San Francisco
2:41 PM	HK2 and HK3 experience	David Ulmert, MD University of California, Los Angeles
2:49 PM	TROP2 and other Promising Targets for Imaging and Therapy	Tanya Stoyanova, PhD University of California, Los Angeles
2:57 PM	CA-IX in renal cell cancer	Brian Shuch, MD University of California, Los Angeles
3:05 PM	Opportunity for RLT in bladder cancer	Vadim Koshkin, MD University of California, San Francisco
3:13 PM	Panel discussion
3:30 PM	Closing comments

PSMA & Beyond Conference

2025 Program

Schedule

Day 1 - Friday, March 28, 2025

Past Events

Main Sponsors

PSMA & Beyond Conference

Search form

You are here

2025 Program

Schedule

Day 1 - Friday, March 28, 2025

Past Events

Main Sponsors